Role of membrane folate-binding protein in the cytotoxicity of 5,10-dideazatetrahydrofolic acid in human ovarian carcinoma cell lines in vitro
1996

Role of folate-binding protein in ovarian cancer treatment

Sample size: 4 publication Evidence: moderate

Author Information

Author(s): S Sen, E Erbal, M D'Incalci, F Bottero, S Canevari, A Tomassetti

Primary Institution: Mario Negri Institute

Hypothesis

The study investigates the cytotoxicity potential of DDATHF as a function of folate-binding protein (FBP) expression.

Conclusion

FBP expression is an important factor for the cytotoxicity of DDATHF, but it is not a reliable predictor of sensitivity to the drug in ovarian cancer cells.

Supporting Evidence

  • FBP expression increased in some ovarian cancer cell lines when grown in low folate conditions.
  • DDATHF showed increased cytotoxicity in ovarian cancer cells when folic acid was depleted from the medium.
  • FBP-tNIH/3T3 cells were significantly more sensitive to DDATHF compared to mock-tNIH/3T3 cells.

Takeaway

This study looks at how a protein that binds folate affects the ability of a cancer drug to kill ovarian cancer cells. It finds that while this protein helps the drug work better, it's not the only thing that matters.

Methodology

The cytotoxicity of DDATHF was evaluated in ovarian carcinoma cell lines using a standard clonogenic assay, with cells grown in media containing different folate concentrations.

Limitations

FBP expression alone cannot predict the sensitivity of ovarian cancer cells to DDATHF.

Want to read the original?

Access the complete publication on the publisher's website

View Original Publication